AstraZeneca Pharma India will launch Calquence in India on Oct 21; stock trades flat

It indicated for the treatment of patients with mantle cell lymphoma (MCL) who have received at least one prior therapy, the company said.

Oct 16, 2020 02:10 IST India Infoline News Service

AstraZeneca Pharma India Limited will launch Calquence in India on October 21, 2020. “We refer to our earlier communication dated March 12, 2020, intimating the receipt of Import and Market Permission in Form CT-20 (Marketing Authorization- Additional Indication) from the Drugs Controller General of India for Acalabrutinib 100mg capsules (Calquence),” the company said in the filing.

Acalabrutinib100mg capsules (Calquence) is: • indicated for the treatment of patients with mantle cell lymphoma (MCL) who have received at least one prior therapy. • indicated for the treatment of patients with chronic lymphocytic leukaemia (CLL)/ small lymphocytic lymphoma (SLL).

AstraZeneca Pharma India Ltd is currently trading at Rs4,267.55, up by Rs0.9 or 0.02% from its previous closing of Rs4,266.65 on the BSE.

The scrip opened at Rs4,279 and has touched a high and low of Rs4,321.05 and Rs4,264.45 respectively.

Related Story